Breastfeeding Reduces Risk of ER-/PR- Breast Cancer

Article

Risk of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative breast cancer is reduced in women who breastfeed and use of oral contraceptives (OCs) does not raise the risk of the disease. So say findings from a population-based study presented at the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research.

Recent Videos
Empowering women to take charge of their health | Image Credit: © piecesofi.com - © piecesofi.com - stock.adobe.com.
Supporting women through menopause with knowledge and care | Image Credit: © SHOTPRIME STUDIO - © SHOTPRIME STUDIO - stock.adobe.com.
How fezolinetant revolutionizes non-hormonal menopause therapy | Image Credit: imsociety.org
Gulf War exposures linked to early menopause in women veterans | Image Credit: linkedin.com.
Vanessa Muñiz discusses benefits of clinical hypnosis against hot flashes | Image Credit: mindbodymedicine.artsandsciences.baylor.edu
Elinzanetant displays positive phase 3 safety and efficacy data against VMS | Image Credit: © toeytoey - © toeytoey - stock.adobe.com.
Lauren Streicher, MD
JoAnne Pinkerton, MD, FACOG, NCMP
Related Content
COVID-19 restrictions linked to reduced preterm birth rates | Image Credit: © Halfpoint - © Halfpoint - stock.adobe.com.

COVID-19 restrictions linked to reduced preterm birth rates

Celeste Krewson, Assistant Editor
September 19th 2024
Article

In a recent study, very preterm birth rates were reduced during COVID-19 lockdown periods vs prepandemic periods.

Read More

Site Logo

How Individually Identifying More HPV Types Enables Better Patient Management and More Precise Care

September 29th 2023
Podcast

Listen

Safety and efficacy of fezolinetant proven in Hispanic women | Image Credit: med.unc.edu

Safety and efficacy of fezolinetant proven in Hispanic women

Celeste Krewson, Assistant Editor;Joshua Fitch, Senior Editor
September 17th 2024
Article

New research shows fezolinetant significantly reduces the frequency and severity of hot flashes in Hispanic women, offering a safer alternative to hormone replacement therapy.

Read More

Site Logo

The Importance of Including Hemoglobinopathies as a Part of Carrier Screening Panels

September 15th 2023
Podcast

Listen

FDA updates warning for liver injury due to fezolinetant

FDA updates warning for liver injury due to fezolinetant

Kevin Kunzmann
September 13th 2024
Article

The FDA upped the recommended rate of liver blood tests for patients initiating fezolinetant on the basis of a post-marketing case report involving serious liver injury.

Read More

Image credit: © highwaystarz - stock.Adobe.com

Investigational nasal spray shows promise vasomotor symptom treatment

Morgan Petronelli, Managing Editor
September 13th 2024
Article

PH80 nasal spray shows promise in reducing menopausal hot flashes, offering an effective and safe non-hormonal treatment option.

Read More

© 2024 MJH Life Sciences

All rights reserved.